Marinomed Biotech AGWBO:MARI +8.74%42 Gross Margin % is 74.66% as of Dec. 2025, which is 547% above its 10-year median of 11.54. GuruFocus rates WBO:MARI with a GF Score™ of 42/100 and a GF Value™ of €18.55 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 734 Biotechnology companies, Marinomed Biotech AG ranks better than 73.98% on this metric.
The historical rank and industry rank for Marinomed Biotech AG's Gross Margin % or its related term are showing as below:
WBO:MARI'
s Gross Margin % Range Over the Past 10 Years
Min: -8.33 Med: 11.54 Max: 81.52
Current: 81.51
During the past 11 years, the highestGross Margin % of Marinomed Biotech AG was 81.52%. The lowest was -8.33%. And the median was 11.54%.
WBO:MARI's Gross Margin % is ranked better than 73.98% of 734
companies
in the Biotechnology industry
Industry Median: 60.795
vs WBO:MARI: 81.51
Marinomed Biotech AG had a gross margin of 74.66% for the quarter that ended in Dec. 2025 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Marinomed Biotech AG was 0.00% per year.
Marinomed Biotech AG (WBO:MARI) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Marinomed Biotech AG had a gross margin of 74.66% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Marinomed Biotech AG Gross Margin % Related Terms
Marinomed Biotech AG Gross Margin % Historical Data
* Premium members only.
The historical data trend for Marinomed Biotech AG's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WBO:MARI vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Marinomed Biotech AG's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Marinomed Biotech AG Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Marinomed Biotech AG's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Marinomed Biotech AG's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Marinomed Biotech AG (WBO:MARI) has a Gross Margin % of 74.66% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Marinomed Biotech AG and its competitors. This is 547% above median its historical median of 11.54. According to the industry distribution chart, Marinomed Biotech AG ranks #191 out of 734 companies in the Biotechnology industry, placing it in the top 26%.
Is Marinomed Biotech AG's Gross Margin % too high?
Marinomed Biotech AG's current Gross Margin % of 74.66% is 547% above median its 10-year median of 11.54. The Biotechnology industry median Gross Margin % is 60.80. Marinomed Biotech AG's value of 74.66% is 22.8% above this industry median. Based on the distribution chart, Marinomed Biotech AG ranks #191 out of 734 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Marinomed Biotech AG has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Marinomed Biotech AG's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Marinomed Biotech AG ranks #191 out of 734 companies for Gross Margin %. This puts Marinomed Biotech AG in the upper half of its industry. The industry median Gross Margin % is 60.80. Marinomed Biotech AG's value of 74.66% is 22.8% above this benchmark. While the company's 10-year median is 11.54 vs. the industry median of 60.80, Marinomed Biotech AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.80, based on 734 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Marinomed Biotech AG's current Gross Margin % of 74.66% is 22.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Marinomed Biotech AG and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Marinomed Biotech AG's current Gross Margin % is 74.66%, which is 547% above median its own 10-year median of 11.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Marinomed Biotech AG stock overvalued right now?
Based on GuruFocus' analysis, Marinomed Biotech AG (WBO:MARI) is currently considered Possible Value Trap. The stock's GF Value™ is €18.55, compared to a current price of €9.95 — trading 46.4% below its estimated fair value. The current Gross Margin % is 74.66%, which is 547% above median its 10-year median of 11.54 and 22.8% above the Biotechnology industry median of 60.80. Marinomed Biotech AG's overall GF Score™ is 42/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Marinomed Biotech AG (WBO:MARI), the current Gross Margin % is 74.66% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Marinomed Biotech AG (WBO:MARI) Overvalued in 2026?
Based on GuruFocus' analysis, Marinomed Biotech AG stock appears to be undervalued.
The current stock price of €9.95 is trading 46.4% below its estimated GF Value™ of €18.55.
GuruFocus considers Marinomed Biotech AG to be Possible Value Trap.
Key valuation signals for WBO:MARI:
Gross Margin %: 74.66% (547% above median its 10-year median of 11.54)
GF Value™: €18.55 vs. price of €9.95 (46.4% below fair value)
Industry Position: 22.8% above the Biotechnology median (#191 of 734)
No single metric tells the full story. See the WBO:MARI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Marinomed Biotech AG is a biopharmaceutical company focusing on the development of products in the field of respiratory and ophthalmological diseases. The company develops products for cough, cold, influenza, allergic rhinitis, and ophthalmic diseases. Its product offerings include virus-blocking nasal sprays, virus-blocking decongestant nasal sprays, virus-blocking lozenges, and virus-blocking throat sprays. The company has two reportable segments which are Virology, Immunology, and other, the majority of revenue generated from the virology segment.
42GF Score
Get the complete analysis for WBO:MARI
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:MARI has been successfully added to your 
